Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Next Previous
Search
Drug Profile

Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Alternative Names: Human parthenogenetic stem cells - International Stem Cell Corporation; Induced pluripotent stem cells - International Stem Cell Corporation; iPS cells - International Stem Cell Corporation; iPSC; Safe iPS cells - International Stem Cell Corporation

Latest Information Update: 01 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator International Stem Cell Corporation
  • Developer International Stem Cell Corporation; University of California at San Francisco
  • Class Antirheumatics; Eye disorder therapies; Hepatoprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Blindness; Crigler-Najjar syndrome; Osteoarthritis
  • Discontinued Diabetes mellitus

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for research development in Osteoarthritis in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Blindness in USA (Intraocular, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Crigler-Najjar syndrome in USA (Implant)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top